Interferon-α induces neurotoxicity through activation of the type i receptor and the GluN2A subunit of the NMDA receptor

Journal of Interferon and Cytokine Research

Volumn 35, Issue 4, 2015, Pages 317-324

  Kessing, Cari F ^a   Tyor, William R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; IFENPRODIL; JANUS KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; STAT1 PROTEIN; AMPA RECEPTOR; CYTOKINE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ARTICLE; BRAIN CELL CULTURE; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; ENZYME ACTIVATION; GLIA; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; POLYMERASE CHAIN REACTION;

MUS; RATTUS;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION; INTERFERON-ALPHA; MICE; NEURONS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RATS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84926487911     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0105     Document Type: Article

References (32)

1. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, Carr DJ, Gold LH, Henriksen SJ, Siggins GR. 1999. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res 835(1):46-61.
2. Dafny N. 1998. Is interferon-alpha a neuromodulator? Brain Res Brain Res Rev 26(1):1-15.
3. Dunn AL, Crnic LS. 1993. Repeated injections of interferonalpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun 7(1):104-111.
4. Fritz-French C, Tyor W. 2012. Interferon-alpha (IFNalpha) neurotoxicity. Cytokine Growth Factor Rev 23(1-2):7-14.
5. Goutieres F, Aicardi J, Barth PG, Lebon P. 1998. Aicardi-Goutieres syndrome: an update and results of interferon-alpha studies. Ann Neurol 44(6):900-907.
6. Jin S, Kawanokuchi J, Mizuno T, Wang J, Sonobe Y, Takeuchi H, Suzumura A. 2007. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 1179:140-146.
7. Kaech S, Banker G. 2006. Culturing hippocampal neurons. Nat Protoc 1(5):2406-2415.
8. Katafuchi T, Take S, Hori T. 1995. Roles of cytokines in the neural-immune interactions: modulation of NMDA responses by IFN-alpha. Neurobiology (Bp) 3(3-4):319-327.
9. Kaul M, Garden GA, Lipton SA. 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410(6831):988-994.
10. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. 2002. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20(17):3703-3718.
11. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. 2013. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler 19(13):1765-1772.
12. Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, Schaefer M. 2006. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 21(3):204-210.
13. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402-408.
14. MacDonald NJ, Kuhl D, Maguire D, Naf D, Gallant P, Goswamy A, Hug H, Bueler H, Chaturvedi M, de la Fuente J, and others. 1990. Different pathways mediate virus inducibility of the human IFN-alpha 1 and IFN-beta genes. Cell 60(5):767-779.
15. Makino M, Kitano Y, Komiyama C, Hirohashi M, Kohno M, Moriyama M, Takasuna K. 2000. Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system. Brain Res 852(2):482-484.
16. Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S. 2007. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential downregulation of IFNAR2. Biochem J 407(1):141-151.
17. Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C. 2000. Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus. Brain Res 885(1):14-24.
18. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. 1996. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25(3):283-291.
19. Paoletti P, Neyton J. 2007. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7(1):39-47.
20. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O, Group CS. 2013. Subcutaneous interferon beta-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 8(8):e74111.
21. Platanias LC, Uddin S, Domanski P, Colamonici OR. 1996. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J Biol Chem 271(39):23630-23633.
22. Quarantini LC, Miranda-Scippa A, Schinoni MI, Sampaio AS, Santos-Jesus R, Bressan RA, Tatsch F, de Oliveira I, Parana R. 2006. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 29(3):138-143.
23. Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, Tyor WR. 1995. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun 9(4):366-377.
24. Rostasy K, Monti L, Yiannoutsos C, Wu J, Bell J, Hedreen J, Navia BA. 2000. NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDS-Dementia-Complex. J Neurovirol 6(6):537-543.
25. Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR. 2009. Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci 29(12):3948-3955.
26. Sas AR, Bimonte-Nelson HA, Tyor WR. 2007. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 21(16):2151-2159.
27. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunze H, Lieb K. 2002. Interferon alpha (IFN alpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26(4):731-746.
28. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. 1992. Interferon-alpha in lupus psychosis. Arthritis Rheum 35(4):417-422.
29. Traugott U, Lebon P. 1988. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 24(2):243-251.
30. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A, Middeldorp JM, Clemens M, Farrell PJ, Giovannoni G, Meier UC. (2012). Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 78(1):15-23.
31. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. 1998. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25(1 Suppl 1):39-47.
32. Wang YH, Bosy TZ, Yasuda RP, Grayson DR, Vicini S, Pizzorusso T, Wolfe BB. 1995. Characterization of NMDA receptor subunit-specific antibodies: distribution of NR2A and NR2B receptor subunits in rat brain and ontogenic profile in the cerebellum. J Neurochem 65(1):176-183.